source
- FDA rejects Summit and Akeso's ivonescimab for narrow lung cancerThe U.S. Food and Drug Administration has turned down ivonescimab, a new cancer therapy being developed by Summit Therapeutics and Akeso, for use in a specific type of lung cancer. Analysts had la…
- Windward Bio launches on Nasdaq after $175 million IPO, secures $50 million from SanofiWindward Bio, a biotech developing drugs for respiratory diseases, completed its initial public offering and began trading on Nasdaq. The offering raised $175 million, with the stock opening at $1…